bi 1701963
Solid Tumors, KRAS Mutation
Boehringer IngelheimPhase 1Active
C
37/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 22/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Solid Tumors, KRAS Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
bi 1823911 Boehringer Ingelheim | Phase 1 | CC |
MIDAZOLAM Boehringer Ingelheim | Phase 1 | CC |
bi 3011441 Boehringer Ingelheim | Phase 1 | NR |
Same molecule, other indications
bi 1701963 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →